Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

7.910
-0.320-3.89%
Volume:99.87M
Turnover:793.97M
Market Cap:91.14B
PE:23.28
High:8.355
Open:8.355
Low:7.820
Close:8.230
52wk High:10.502
52wk Low:6.257
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.41
T/O Rate:0.87%
Dividend:0.33
Dividend Rate:4.17%
EPS(LYR):0.340
ROE:20.90%
ROA:10.70%
PB:2.06
PE(LYR):23.28
PS:2.47

Loading ...

CSPC Pharma Presents Results of Tumor Drug Studies at ESMO Congress 2026

MT Newswires Live
·
1 hour ago

CSPC Pharma Reports Phase I/II Results for Anti-PD-1/IL-15 Bispecific Fusion Protein SYS6090 (JMT108) Monotherapy in Advanced Solid Tumors at 2026 ESMO Congress Rapid Oral Presentation

Stock News
·
2 hours ago

CSPC's Sys6090 Shows 40% Response Rate in Evaluable Liver Cancer Patients in Early-Stage Trial

Reuters
·
2 hours ago

Movement Alert|CSPC PHARMA Falls 3.04% in Regular Trading, Breast Cancer Phase III Data Fails to Offset Broader Pharma Weakness

Market Focus
·
10 hours ago

Linklogis-W Sees Strong Revenue Growth in First Three Quarters, Advances AI Strategy and Global Expansion

Stock News
·
12 hours ago

CSPC Pharmaceutical Publishes Updated Phase III OS Results for Anbenitamab in Her2-Positive Advanced Gastric Cancer

Reuters
·
20 hours ago

CSPC Pharma’s Anbenitamab + HB1801 Regimen Cuts Progression Risk by 54% in Phase III HER2-Positive Breast Cancer Trial

Bulletin Express
·
Yesterday

CSPC Pharma's Anbenatamab Combination Shows Improved Overall Survival in Phase III HER2-Positive Gastric/GEJ Adenocarcinoma Trial at 2026 ESMO Congress

Stock News
·
Yesterday

CSPC’s Anbenitamab Regimen Cuts Death Risk 61% in Phase III Gastric Cancer Trial

Reuters
·
Yesterday

CSPC Pharmaceutical - Updated Phase Iii Os Results for Anbenitamab in Her2-Positive Advanced Gastric Cancer

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical - no Treatment-Related Deaths in Anbenitamab Group; 5 in Control Group

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical Group Stock Slides 1.4% in Hong Kong

Dow Jones
·
Yesterday

New Growth Drivers Take Center Stage as China's Economy Accelerates

Deep News
·
Oct 25

CSPC Pharma's Injection for Rare Autoimmune Disease Gets Regulatory Nod in China

MT Newswires Live
·
Oct 23

Movement Alert|CSPC PHARMA Falls 3.11% in Regular Trading, gMG Drug Approval Fails to Lift Shares

Market Focus
·
Oct 23

CSPC Pharma Receives NMPA Green Light for Enlida® (Batoclimab) Injection in Adult gMG Patients

Bulletin Express
·
Oct 23

CSPC Pharmaceutical Wins China Approval for Batoclimab to Treat Generalized Myasthenia Gravis

Reuters
·
Oct 23

CSPC Pharmaceutical - Batoclimab Injection (Enlida) Obtains Drug Registration Certificate from Nmpa

THOMSON REUTERS
·
Oct 23

CSPC Pharma Initiates Phase II Study of Small-Molecule RSV Inhibitor SYH2066 in China

Bulletin Express
·
Oct 22

CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Sys6043 for Triple-Negative Breast Cancer in China

THOMSON REUTERS
·
Oct 22